OserLab
@Oser_Lab
Followers
498
Following
535
Media
1
Statuses
120
OserLab @DanaFarber @harvardmed Seeks To Identify New Targeted Therapies For Small Cell Lung Cancer. Tweets/Views are my own.
Boston, MA
Joined November 2019
Grateful to all of our collaborators including @yejingge at MDACC. https://t.co/L6KF3PkMgy
0
0
2
Excited to share our new work in Dev Cell ( https://t.co/BjVkuDiBXi), led by my highly talented postdoc Deli Hong! We find that loss of NOTCH2 creates a dependency on TRIM28, highlighting TRIM28 as a potential therapeutic target in NOTCH2-deficient or low-NOTCH2 SCLC.
4
3
14
This study was led by my highly talented postdoctoral fellow Shilpa Singh and was an outstanding collaboration with Circle Pharma and Deepak Nijhawan's lab at UTSW. @DanaFarberNews @DFarberThoracic.
0
0
4
Thrilled to share our new work published in Nature ( https://t.co/6KIgZiDhMN). We report an exciting new potential therapeutic strategy with a fascinating mechanism of action for cancers with a compromised G1–S cell cycle checkpoint, including SCLC. https://t.co/8UyaKWbecQ
nature.com
Nature - Dual cyclin A/B RxL inhibitors selectively kill small cell lung cancer cells and other cancer cells with high E2F activity.
9
25
131
🧩 New paper out in Nature Communications! "Unveiling the hidden interactome of CRBN molecular glues" Huge thanks to our incredible team and collaborators who made this possible! 📖 Read the full open-access article here:
nature.com
Nature Communications - Induced proximity by molecular glues is a strategy that leverages the recruitment of proteins to facilitate their modification or degradation. Here the authors present...
1
13
71
This is the first year I’m riding the Pan Mass Challenge in 2 weeks! I’m riding in honor of both my parents. It will be a deeply meaningful ride for me. All proceeds go toward cancer research at Dana Farber. Please donate if you can (details/link below)
profile.pmc.org
Dear Friends, Family, and Colleagues,
0
1
10
Great talk by Dr. Shilpa Singh @Oser_Lab @DanaFarber looking at Cyclin A/B RxL Macrocyclic Inhibitors in SCLC w/ high E2F activity. Beautiful example of bridging lab to clinical research. Phase 1 trial is recruiting. #SCLC25 @SclcSMASHERS
2
6
9
I am very excited to announce that I have started my lab at the Brigham and Women’s Hospital and Harvard Medical School in the Department of Pathology. We are seeking talented, curious, individuals and recruiting at all levels! https://t.co/rXEcDwQsPS 1/2
9
16
221
Thoracic oncologist Matt Oser @Oser_Lab, and scientist @CKadoch, @kadochlab at Dana-Farber have discovered a way to stunt the function of a driver of small cell lung cancer. The finding points to a potential treatment (cont) https://t.co/NAwOmSMuPz
0
3
15
Thrilled to visit @MDAndersonNews next week and present some recent work from our lab on SCLC. Thank you @LeXiuning for inviting and hosting me!
I am excited to host Dr. Matt Oser from DFCI @Oser_Lab as our GrandRound speaker next week! Matt is a prominent physician-scientist, a colleague in thoracic oncology, a peer Damon-Runyon investigator, and a dear friend @DamonRunyon @LaurenByersMD @MDAndersonNews @EGFRResisters
1
1
15
Excited to see our collaborative work with @Oser_Lab @DanaFarber @DanaFarberNews on #SCLC #lungcancer out in @Cancer_Cell, identifying chemically targetable #BAFcomplex chromatin regulatory dependencies and providing foundation for new clinical studies for this aggressive cancer.
Online Now: Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer https://t.co/c3vWNzt3YL
2
6
24
Exciting to see our @kadochlab and @Oser_Lab collaborative study focused on mSWI/SNF chromatin remodeling complexes in small cell lung cancer out in @Cancer_Cell! This is one of 4+ studies published/soon to be published highlighting the potential for #BAF disruption in SCLC!
Excited to see our collaborative work with @Oser_Lab @DanaFarber @DanaFarberNews on #SCLC #lungcancer out in @Cancer_Cell, identifying chemically targetable #BAFcomplex chromatin regulatory dependencies and providing foundation for new clinical studies for this aggressive cancer.
0
8
65
Thank you @DanaFarberNews for featuring our new work, a wonderful collaborative effort with @CKadoch @kadochlab, published today in @Cancer_Cell. Congrats to Leslie Duplaquet and Kevin So who together led this study and to computational biologist Alex Ying.
A study in @Cancer_Cell, led by Matthew Oser, MD, PhD (@Oser_Lab) & Cigall Kadoch, PhD (@CKadoch) at @danafarber identify SWI/SNF inhibitors as a potential targeted treatment for POU2F3-positive small cell lung cancer, accounting for 12% of cases. Study ▶️ https://t.co/reoHu0eeFa
0
0
20
Lastly, thank you to all of our other collaborators as well as our reviewers and editor which greatly improved our paper during the revision process. @DamonRunyon @DanaFarberNews.
0
0
4
Together this study suggests that mSWI/SNF complex inhibition should be tried as a therapeutic strategy for patients with POU2F3-positive SCLC, which are the least responsive SCLC subtype to SOC chemotherapy. 6/
1
1
6
In another great collaboration with @BenDrapkin, we found that a pure non-neuroendocrine POU2F3-positive SCLC PDX model that was refractory to first-line chemotherapy was highly sensitive to SMARCA4/2 inhibition and BRD9 degradation. 5/
1
1
6
We uncover the underlying mechanisms by which the mSWI/SNF complex and the ncBAF complex govern the POU2F3 oncogenic program. 4/
1
0
3
We find that all POU2F3-positive SCLC cell lines are highly sensitive to clinical-grade mSWI/SNF inhibitors (SMARCA4/2 inhibitors) while only pure non-neuroendocrine POU2F3 SCLC cell lines are sensitive to disruption of ncBAF (BRD9 degraders). 3/
1
1
4
This was an wonderful collaboration with @CKadoch @kadochlab and huge congrats to co-first authors Leslie Duplaquet PhD (my lab) and Kevin So (Kadoch lab) and also Alex Ying from Kadoch lab. 2/
1
0
3